Related Experiment Video

Updated: Jun 8, 2026

Development of a Novel Internal Fixation Model for Rat Radial Fractures: Fracture Healing Assessment and Dorsal Root Ganglion Isolation
11:21

Development of a Novel Internal Fixation Model for Rat Radial Fractures: Fracture Healing Assessment and Dorsal Root Ganglion Isolation

Published on: March 13, 2026

Glucagon-Like Peptide-1 Receptor Agonist Use and Postoperative Outcomes After Distal Radius Fracture Fixation in

Ankit Choudhury1, Jacob D Kodra1, Lucas Mathson1

  • 1Department of Orthopaedic Surgery, Medical College of Wisconsin, Milwaukee, USA.

Hand (New York, N.Y.)
|June 7, 2026
PubMed
Abstract

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are safe for patients with type 2 diabetes undergoing distal radius fracture surgery. GLP-1 RA use was not linked to more complications and was associated with less 180-day healthcare use.

Area of Science:

  • Orthopedic Surgery
  • Endocrinology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are common for type 2 diabetes mellitus (T2DM).
  • Perioperative safety of GLP-1 RAs in hand/wrist surgery is not well-established.
  • Distal radius fracture fixation is a common orthopedic procedure in T2DM patients.

Purpose of the Study:

  • Evaluate the association between preoperative GLP-1 RA use and postoperative outcomes.
  • Assess medical and surgical complications after distal radius fracture fixation.
  • Determine the impact of GLP-1 RAs on healthcare utilization.

Main Methods:

  • Retrospective cohort study using the TriNetX Network (2018-2024).
  • 1:1 propensity score matching of T2DM patients undergoing distal radius fracture fixation.
  • Comparison of 90-day medical and 180-day surgical complications and healthcare use between GLP-1 RA users and non-users.

Main Results:

  • No significant difference in composite 90-day medical or 180-day surgical complications.
  • Individual adverse events were rare and similar between groups.
  • GLP-1 RA use was linked to reduced 180-day emergency department visits and hospital readmissions.

Conclusions:

  • Preoperative GLP-1 RA exposure is not associated with increased complications in T2DM patients undergoing distal radius fracture surgery.
  • GLP-1 RAs may be safe for perioperative use in this patient population.
  • Findings suggest reduced 180-day healthcare utilization with GLP-1 RA use, warranting prospective studies.
Keywords:
distal radiusdistal radius fracturedistal radius open reduction and internal fixationglucagon-like peptide-1 receptor agonistshand surgeryhealthcare utilizationpostoperative complicationstype 2 diabetes mellitus

More Related Videos

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis02:08

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis

Published on: July 5, 2024

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...